Sachetta LLC Grows Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Sachetta LLC lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 11.8% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 7,599 shares of the company’s stock after purchasing an additional 802 shares during the quarter. Sachetta LLC’s holdings in Johnson & Johnson were worth $1,232,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in JNJ. China Universal Asset Management Co. Ltd. purchased a new stake in Johnson & Johnson in the first quarter valued at approximately $765,000. Empowered Funds LLC grew its stake in shares of Johnson & Johnson by 46.7% during the 1st quarter. Empowered Funds LLC now owns 101,237 shares of the company’s stock valued at $16,015,000 after buying an additional 32,244 shares during the period. Payden & Rygel Investment Group acquired a new position in Johnson & Johnson in the first quarter valued at $14,379,000. Mattern Capital Management LLC grew its position in Johnson & Johnson by 6.9% during the first quarter. Mattern Capital Management LLC now owns 48,191 shares of the company’s stock valued at $7,623,000 after acquiring an additional 3,091 shares during the period. Finally, Shell Asset Management Co. grew its holdings in shares of Johnson & Johnson by 9.7% during the 1st quarter. Shell Asset Management Co. now owns 17,728 shares of the company’s stock worth $2,804,000 after purchasing an additional 1,562 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

JNJ has been the topic of several research reports. Guggenheim raised their price target on shares of Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th. Daiwa Capital Markets downgraded shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and cut their target price for the company from $160.00 to $150.00 in a research note on Tuesday, July 23rd. Citigroup upped their price target on shares of Johnson & Johnson from $180.00 to $185.00 and gave the stock a “buy” rating in a research report on Wednesday, October 16th. Wolfe Research began coverage on Johnson & Johnson in a research report on Friday, November 15th. They issued an “outperform” rating and a $190.00 price objective on the stock. Finally, Morgan Stanley upped their target price on Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 16th. Seven research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $175.94.

Johnson & Johnson Trading Down 1.2 %

Shares of NYSE JNJ opened at $152.97 on Wednesday. The stock has a market capitalization of $368.29 billion, a P/E ratio of 22.14, a PEG ratio of 2.74 and a beta of 0.53. The stock’s 50 day moving average price is $160.83 and its two-hundred day moving average price is $156.19. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $168.85.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, beating the consensus estimate of $2.21 by $0.21. The company had revenue of $22.47 billion during the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The business’s revenue was up 5.2% compared to the same quarter last year. During the same period in the prior year, the company earned $2.66 earnings per share. On average, analysts anticipate that Johnson & Johnson will post 9.93 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be issued a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.24%. The ex-dividend date of this dividend is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio (DPR) is 71.78%.

Insider Buying and Selling

In related news, VP Robert J. Decker sold 5,635 shares of the firm’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the transaction, the vice president now owns 18,973 shares of the company’s stock, valued at $3,131,683.38. This trade represents a 22.90 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.